Eranz

Quick links to important sections

Eranz

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eranz

Eranz is a prescription-only therapeutic agent known chemically by its active compound, Donepezil hydrochloride. It is classified as a selective acetylcholinesterase inhibitor (AChEI), a class of medicines recognized for their use in supporting cognitive function.


Quick Facts

Property Description
Active Ingredient Donepezil hydrochloride
Pharmacological Class Selective Acetylcholinesterase Inhibitor (AChEI)
Route of Administration Oral
Origin Synthetic compound
General Purpose Support and maintenance of cognitive function

Defining Donepezil: Class, Origin, and Action

The identity of Eranz is anchored in its sole active component, Donepezil hydrochloride, which is recognized as a synthetic molecule and a piperidine derivative. Its pharmacological classification as a selective acetylcholinesterase inhibitor means its core mechanism focuses on temporarily blocking the enzyme that breaks down the neurotransmitter acetylcholine in the brain. This mechanism results in enhancing cholinergic neurotransmission for improving cognitive function. This action serves the general therapeutic purpose of promoting stable nerve communication to help support and maintain key thinking and memory processes.

Composition and Available Oral Forms

Eranz is a single-active-ingredient product administered via the oral route. The medication is available in several dosage forms, including the standard film-coated oral tablet, the orally disintegrating tablet (ODT), and an oral solution. The ODT, which dissolves quickly on the tongue, is a distinctive feature that provides a practical alternative for patients, particularly within the elderly population, who may experience difficulty swallowing conventional tablets. The composition of all preparations focuses on the effective and consistent oral delivery of the active Donepezil hydrochloride compound.

Regulatory References

  1. MedlinePlus, NIH

What side effects are possible with Eranz?

Safety Profile Overview

The safety characteristics of Eranz (Donepezil hydrochloride) are primarily defined by the drug's mechanism as a cholinesterase inhibitor, with potential effects documented across several physiological systems in regulatory labeling. Adverse reactions are classified by frequency, based on clinical data and post-marketing reports.

Very Common adverse reactions, defined as occurring in more than 1 in 10 patients, include Nausea, Diarrhoea, and Headache. Common effects, occurring in 1 in 10 to 1 in 100 patients, include Insomnia, Vomiting, Dizziness, Muscle cramps, and Fatigue, alongside psychiatric effects such as Hallucinations and Aggressive behaviours.

Serious Adverse Reactions and Safety Constraints

Official documents list rare but serious adverse reactions across several System-Organ Classes (SOC). Potential Cardiac Disorders include Bradycardia (slow heart rate), Sino-atrial block, and post-marketing reports of QTc prolongation. Gastrointestinal Disorders include the risk of Gastric/duodenal ulcers and Gastrointestinal bleeding, particularly in patients with a history of ulcer disease or those concurrently using Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Other serious reactions include Seizures and Neuroleptic Malignant Syndrome (NMS). Safety notes specify that certain common effects like nausea and vomiting are often transient and are more frequently observed at the initiation of treatment or following dose increases.

Overdose and Emergency Response

Overdosage with Eranz (Donepezil hydrochloride) can lead to an exaggerated cholinergic crisis, requiring immediate medical intervention. The official regulatory profile dictates that emergency medical care must be sought at once if an overdose is suspected.

Documented Manifestations

The documented clinical signs of overdosage are consistent with cholinergic overstimulation. These include severe nausea, severe vomiting, drooling (salivation), increased sweating, generalized muscle weakness, and confusion. More serious manifestations affecting the cardiovascular system include bradycardia (slow heart rate) and hypotension (low blood pressure).

Severe Risks and Required Action

Overdose can result in life-threatening outcomes, specifically heart block, severe syncope, and the potential for respiratory depression leading to muscle paralysis. Due to these risks, regulatory labeling requires that patients be hospitalized, and continuous cardiac monitoring is mandatory. Anticholinergics, such as Atropine, are the designated management agent for counteracting the effects of the cholinergic crisis, administered intravenously and titrated according to clinical need. Gastric lavage may also be performed in the early stages following ingestion. Regulatory documents note that patients with low body weight (typically leq 55 kg) may experience higher drug concentrations, which could increase the potential for toxicity.

Therapeutic Uses of Eranz

Eranz is generally used to offer targeted symptomatic relief and supports patients across key therapeutic domains. It is commonly used for managing symptoms that interfere with daily functioning associated with certain conditions. The medication may assist with managing symptoms related to cognitive and functional stability.

The medication is considered relevant when supportive symptom management is appropriate, as it supports the patient during difficult episodes and contributes to easing the overall symptom load during periods of heightened symptoms. Eranz is utilized in situations involving certain distressing symptoms.

It is applied across therapeutic areas that involve heightened patient distress and conditions presenting with episodic or fluctuating manifestations. The medication is considered relevant for easing pronounced symptoms, supporting patients during difficult episodes, and assisting with maintaining functional stability.

Quick Fact: Support in Managing Functional Strain

Quick Fact: Support in Managing Functional Strain - Eranz is commonly used to help with symptoms that create noticeable interference with daily stability. It supports the patient during phases of increased discomfort or tension.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Eranz?

The population eligibility for Eranz (Donepezil hydrochloride) is explicitly defined by regulatory authorities based on patient characteristics and medical status.

Absolute Exclusions and Contraindications

The medicine is contraindicated and must not be used in patients with a known hypersensitivity to donepezil hydrochloride or to any drugs belonging to the same chemical class, piperidine derivatives.

Age and Developmental Status

Use is not recommended in children and adolescents (patients under 18 years of age). This exclusion is based on the fact that safety and efficacy have not been established in this age group. Eranz is approved for use in the adult and older adult population.

Conditional Use and Restrictions

Caution is required for use in patients with certain pre-existing conditions. This includes individuals with cardiac conduction abnormalities such as sick sinus syndrome, due to the potential for bradycardia. Patients with a history of peptic ulcer disease or those concurrently receiving Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) require close monitoring for gastrointestinal bleeding.

Pregnancy and Lactation: Use is not recommended during pregnancy unless clearly necessary. Women taking the medicine should not breastfeed.

What should I know about interactions with other medicines?

The official interaction profile of Eranz (Donepezil hydrochloride) is governed by both pharmacokinetic and pharmacodynamic constraints, as documented in regulatory labeling.

Pharmacokinetic and Exposure Alterations

Donepezil metabolism involves the cytochrome P450 isoenzymes CYP3A4 and CYP2D6. Co-administration with inhibitors of these enzymes, such as ketoconazole or quinidine, is formally documented to increase donepezil plasma concentrations, altering systemic exposure. Conversely, strong enzyme inducers like rifampicin, phenytoin, and alcohol may increase the rate of donepezil elimination, potentially reducing drug levels. Caution is advised with these combinations.

Pharmacodynamic Interactions and Restrictions

The official labeling advises avoiding co-administration with other acetylcholinesterase inhibitors, cholinergic agonists, or cholinergic antagonists due to the potential for additive or antagonistic pharmacodynamic effects. Specific combinations carry formally documented risks: the concurrent use of donepezil with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) carries an increased risk of gastrointestinal ulcers and bleeding. Furthermore, a documented risk exists of exaggerating the effects of depolarizing neuromuscular blocking agents, such as succinylcholine, when used during anesthesia. Caution is also advised when co-administered with medicinal products known to prolong the QTc interval.

Population-Specific Interactions

Genetic differences are noted, as clearance rates for donepezil are documented to differ based on a patient’s CYP2D6 metabolizer status. Additionally, dose escalation in cases of mild to moderate hepatic impairment requires caution due to the possibility of increased drug exposure.

Mechanism of Action

Eranz is an organic, non-peptidic molecule that functions as a highly selective, competitive antagonist of the human Hormone Receptor Alpha (HRA) at the cellular level. Following systemic absorption, Eranz achieves selective distribution to targeted cell populations where it binds directly to the HRA ligand-binding domain.

This binding event effectively prevents the association of the endogenous agonist ligand with the HRA, thereby stabilizing the receptor in an inactive confirmation. The prevention of HRA-agonist interaction blocks the subsequent dimerization and nuclear translocation of the receptor complex. Consequently, the drug inhibits the HRA-mediated transcription of downstream target genes. This pathway modulation ultimately results in the selective suppression of protein synthesis driven by HRA signaling, leading to a modified physiological response at the system level.

Dosage and Administration Information

How Eranz is Used: Official Administration Guidelines

Eranz (Donepezil hydrochloride) is a prescription-only medication administered via the oral route (tablet, orally disintegrating tablet (ODT), or oral solution). Standardized protocols exist for its intake, dosing, and schedule, which should be strictly followed.


Official Dosing and Schedule

Regimen Element Official Guideline
Starting Dose 5 mg administered once daily.
Titration The 5 mg dose must be maintained for 4 to 6 weeks before increasing to 10 mg once daily.
Maximum Dose 10 mg once daily or 23 mg once daily.
Frequency/Timing Taken once daily in the evening, just prior to retiring. Can be taken with or without food.

Practical Administration and Limitations

All standard film-coated tablets should be swallowed whole with water and must not be split, crushed, or chewed. Orally Disintegrating Tablets (ODT) should be allowed to dissolve on the tongue before swallowing.

Treatment must be initiated and supervised by a physician experienced in the relevant therapeutic area, and a caregiver should monitor the drug intake. If doses are missed for more than seven consecutive days, consulting a physician is recommended, as re-titration starting from the 5 mg dose may be required.

Population-Specific Rules: A similar dose schedule may be followed for patients with renal impairment. For patients with mild to moderate hepatic impairment, dose escalation should be based on individual tolerability due to potential for increased exposure. Use is not recommended in children and adolescents under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eranz (Donepezil)


Evidence for Use in Mild to Moderate Alzheimer's Disease

The evidence landscape for Eranz primarily consists of studies that focus on its evaluation for conditions characterized by functional limitations, specifically in patients with mild to moderate Alzheimer's Disease (AD). Researchers studied the compound in numerous short-term to intermediate-term Randomized Controlled Trials (RCTs), many of which compared the outcomes of patients receiving Eranz against those receiving a placebo (an inactive substance). These RCTs form the evidence base for the systematic reviews and meta-analyses used to evaluate the medicine.

In these studies, research examined changes in patient status using standardized scales. These scales included assessments of cognitive function—which is used to measure thinking and memory processes—and global function, which provides a clinician's overall view of the patient's condition. Trials reported measurements of change on the cognitive and global rating scales that were observed over the initial 12 to 24-week study periods. While research highlights changes measured during the study period on these scales, there is an absence of substantial evidence characterizing the medicine's potential to cure the underlying disease or stop its ultimate progression.


Evidence for Use in Moderate to Severe Alzheimer's Disease

Research has evaluated Eranz in patients with more advanced disease severity, where symptoms may vary in intensity. The evidence for this population includes placebo-controlled trials and comparative studies that examined different dosing strategies. Researchers utilized specialized outcome measures like the Severe Impairment Battery (SIB) to monitor thinking and memory processes. Studies reported patterns observed in these more impaired populations over approximately 24-week observation periods. When researchers examined different doses, some trials reported measurements of change on cognitive status, but studies observed mixed findings on global function measures.


Key Limitations and Research Gaps

Scientific reviews consistently point to several limitations in the evidence base for Eranz. The research conducted primarily focused on symptomatic changes; the evidence does not characterize whether the medicine alters the underlying course of the disease. Another area where data are still emerging is the effect on a patient's Quality of Life (QoL). Studies have provided mixed findings, and a clear, consistent measured effect on patient-reported outcomes has not been established. The research also includes trials for investigational uses like Mild Cognitive Impairment (MCI), where evidence is limited and findings are often mixed or conflicting across different trials.

Key Studies & References

  1. Donepezil for mild cognitive impairment - Cochrane Review

Frequently Asked Questions (FAQ)

Common questions about Eranz (FAQ)


Q: Is Eranz the same as Aricept, or are they different drugs?

Eranz is a brand name for the medicine. The active ingredient in Eranz is donepezil hydrochloride, which is the same active ingredient found in the brand name medicine Aricept. This active compound is also widely available as a generic medication.


Q: Does Eranz improve memory, or does it only slow decline?

The medicine is indicated for managing the symptoms of dementia of the Alzheimer's type. Official information indicates that it is not a cure and does not stop the disease from worsening; however, studies have shown it may help to improve symptoms or slow the loss of thinking and memory abilities.


Q: How long do the initial side effects of Eranz usually last?

Common initial side effects, such as nausea and vomiting, are generally considered transient (temporary). Regulatory information indicates these effects sometimes last one to three weeks but typically lessen or resolve as treatment continues.


Q: Does Eranz interact with common over-the-counter pain relievers like ibuprofen?

Official labeling advises caution with co-administration of Eranz and Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes medicines like ibuprofen. Taking Eranz with NSAIDs carries an increased risk of gastrointestinal ulcers and bleeding.


Q: Is Eranz appropriate for elderly people, especially those with other health issues?

The medicine has been studied in the older adult population and is approved for use in adults. However, close monitoring is required by the healthcare provider for patients with certain pre-existing conditions, such as heart problems, stomach ulcers, or lung diseases.


Q: Why do some people say they feel worse when they first start Eranz?

The medicine's mechanism of action can predictably lead to adverse effects like nausea and vomiting. These effects tend to appear more frequently at the initiation of treatment or when the dose is increased, which is related to the transient nature of adverse effects seen early in treatment.


Q: Is Eranz FDA-approved for its main uses?

Yes, regulatory documents confirm that the medicine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of dementia of the Alzheimer's type.


Q: Is Eranz appropriate for people who are highly sensitive to medications?

Official labeling lists hypersensitivity as a contraindication. This means the medicine must not be used by patients who have a known allergy or severe reaction to donepezil hydrochloride or other medicines in the piperidine chemical class.


Q: Are there generic versions of Eranz available?

Yes. The active ingredient in Eranz, donepezil hydrochloride, is available in the United States and globally as a generic medication.


Q: What are the typical benefits a patient might notice after several months on Eranz?

Clinical studies have shown benefit by measuring improvements in cognitive function, which covers areas like memory, orientation, and attention. Benefit is also assessed based on a clinician's overall view of the patient's condition (global function).


Q: How quickly should someone expect to feel the effects of Eranz?

After taking a dose, the medicine reaches its maximum levels in the blood in about 3 to 4 hours. However, the earliest clinical responses to treatment are typically assessed after the starting dose has been maintained for at least four to six weeks.


Q: What is the difference between Eranz and Namenda?

The two medicines belong to different pharmacological classes. Official product information notes that donepezil has been approved for use in combination with the medicine memantine (brand name Namenda) to manage moderate and severe forms of Alzheimer's dementia.


Q: Can taking Eranz cause vivid or strange dreams?

Official regulatory documents list changes in sleep. Abnormal dreams and nightmares have been reported as adverse reactions during clinical studies.


Q: Are there any specific vitamins or supplements that shouldn't be taken with Eranz?

Regulatory information advises informing a healthcare provider about all prescription and nonprescription medications, as well as vitamins, nutritional supplements, and herbal products being taken, as part of a full disclosure of all products being used.


Q: Can Eranz be taken indefinitely, or is it only for a set period?

Maintenance treatment can be continued for as long as a therapeutic benefit is present. The clinical benefit of the medicine should be reassessed on a regular basis by the treating physician to determine if continued use is appropriate.


Q: What are the long-term effects of using Eranz?

Regulatory agencies have advised of a potential risk of QT interval prolongation, a heart rhythm change, during use. This risk requires that healthcare providers use caution and monitoring, particularly in patients with pre-existing heart conditions.


Q: Why do doctors often prescribe Eranz along with other medications?

Regulatory information indicates that the medicine has been approved for use in a combination product with memantine for moderate and severe forms of Alzheimer's dementia. This is the official rationale for co-administration in more advanced stages.


Q: Is Eranz habit-forming, or can you stop taking it without withdrawal symptoms?

The medicine is not classified as habit-forming. However, abruptly stopping the medicine has been associated with a decline in cognitive function, and re-titration from the lowest dose may be required if doses are missed for an extended period.


Q: What happens if Eranz is stopped abruptly?

Abruptly stopping the medicine has been associated with a decline in cognitive function. If the medicine is suspended for more than seven consecutive days, regulatory guidance suggests consulting a physician, as a new titration starting from the lowest dose may be required.


Q: Are there any dietary restrictions recommended while on Eranz?

No specific dietary restrictions are mandated by official guidance. Regulatory information states that unless directed otherwise by a healthcare professional, patients should continue their normal diet.


Q: Does Eranz cause weight gain or weight loss?

Official safety data reports that weight loss has been reported as an adverse reaction during clinical trials. Anorexia (loss of appetite) is also listed as an adverse effect, particularly with higher doses.


Q: What should a patient do if they develop a rash after starting Eranz?

Official guidance recommends seeking emergency medical attention if a patient experiences signs of a severe allergic reaction, such as hives, difficulty breathing, or swelling.


Q: What is the maximum duration of action for a single dose of Eranz?

The terminal disposition half-life (the time it takes for half the drug to be eliminated from the body) is approximately 70 hours. This extended duration means the medicine remains in the body for a considerable time after a single dose.


Q: What are the signs that Eranz might not be working for a patient?

The clinical benefit should be reassessed on a regular basis by the treating physician. This evaluation determines if continued therapeutic benefit exists, using standardized clinical measures.


Q: Can Eranz be taken with common cold and flu medications?

Regulatory information advises informing a healthcare provider about all prescription and nonprescription medications being taken. This includes common cold and flu medicines due to the potential for drug interactions.


Q: Can Eranz affect a person's ability to drive or operate machinery?

Official guidance recommends that the treating physician regularly evaluate the patient's ability to drive or operate complex machinery. This is due both to the underlying condition and the medicine's potential to cause side effects such as tiredness, dizziness, and muscle cramps.


Q: Does Eranz have a black box warning?

No. Official documents confirm that the FDA Prescribing Information for the oral form of the medicine does not contain a Boxed Warning (also known as a Black Box Warning).

How should Eranz be stored and disposed of?

Official Storage and Disposal Instructions

Eranz (donepezil hydrochloride) must be stored under specific conditions to maintain its stability and effectiveness, as mandated by regulatory documents.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (e.g., between 20°C and 25°C). Do not freeze and keep away from excess heat.
Protection Must be stored to protect from moisture and direct light.
Packaging Keep the product in the original container, and ensure the container is tightly closed.
Safety Mandate The medication must be kept strictly out of the reach of children.

Disposal Instructions

Any unused or expired Eranz must be disposed of in accordance with local and national regulations. To protect privacy and prevent misuse, official guidance recommends scratching out identifying information on the prescription label before discarding the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eranz found in:

A-Z Index: